



News Release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Takeda Announces Pricing of its Unsecured U.S. Dollar-Denominated Senior Notes

OSAKA, Japan, June 28, 2024 and CAMBRIDGE, Massachusetts, June 27, 2024 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK, “Takeda”) announced today that it has determined the pricing of its unsecured U.S. dollar-denominated senior notes (the “Notes”), as outlined below. The offering of the Notes is being made pursuant to Takeda’s shelf registration statement on Form F-3 (File No. 333-280469) filed with the Securities and Exchange Commission on June 26, 2024 and a supplement to the prospectus therein.

The Notes will be direct, unsecured and unsubordinated general obligations of Takeda and will have the same rank in liquidation as all of Takeda’s other unsecured and unsubordinated debt. Takeda intends to use the proceeds from the offering of the Notes to fund the respective tender offers of its wholly-owned subsidiaries, Shire Acquisitions Investments Ireland Designated Activity Company (“SAIIDAC”) and Baxalta Incorporated (“Baxalta”) announced today in respect of the 3.200% senior notes due September 23, 2026 issued by SAIIDAC and the 4.000% senior notes due June 23, 2025 issued by Baxalta. Takeda intends to use the remainder of the proceeds of the offering of the Notes to repay outstanding borrowings under its commercial paper facility.

Unsecured U.S. Dollar-Denominated Senior Notes Due 2034

(a) Issue Amount	USD 1,100 million
(b) Coupon	5.300% per annum
(c) Issue Price	99.724% of the principal amount
(d) Maturity Date	July 5, 2034
(e) Issue Date	July 5, 2024
(f) Pledge	None
(g) Security	None
(h) Securities Exchange on which the notes will be listed	None

Unsecured U.S. Dollar-Denominated Senior Notes Due 2044

(a) Issue Amount	USD 800 million
(b) Coupon	5.650% per annum
(c) Issue Price	99.561% of the principal amount
(d) Maturity Date	July 5, 2044
(e) Issue Date	July 5, 2024
(f) Pledge	None
(g) Security	None
(h) Securities Exchange on which the notes will be listed	None

Unsecured U.S. Dollar-Denominated Senior Notes Due 2054

(a) Issue Amount	USD 600 million
(b) Coupon	5.650% per annum
(c) Issue Price	99.570% of the principal amount
(d) Maturity Date	July 5, 2054
(e) Issue Date	July 5, 2024
(f) Pledge	None
(g) Security	None
(h) Securities Exchange on which the notes will be listed	None

Unsecured U.S. Dollar-Denominated Senior Notes Due 2064

(a) Issue Amount	USD 500 million
(b) Coupon	5.800% per annum
(c) Issue Price	99.537% of the principal amount
(d) Maturity Date	July 5, 2064

(e) Issue Date	July 5, 2024
(f) Pledge	None
(g) Security	None
(h) Securities Exchange on which the notes will be listed	None

This press release does not constitute an offer to sell or a solicitation of an offer to buy, or an offer to purchase or a solicitation of an offer to sell, any securities. The securities have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the prospectus, prospectus supplement or the shelf registration statement.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Contacts

Investor Relations

Christopher O'Reilly
christopher.oreilly@takeda.com
+81 (0) 3-3278-2543

Media Relations

Brendan Jennings
brendan.jennings@takeda.com
+81 (0) 80-2705-8259

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of

health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: <https://www.takeda.com/investors/sec-filings-and-security-reports/> or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

###